Research programme: cannabinoid receptor agonists - MakScientific/Endo Pharmaceuticals

Drug Profile

Research programme: cannabinoid receptor agonists - MakScientific/Endo Pharmaceuticals

Latest Information Update: 07 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MakScientific
  • Developer Endo Pharmaceuticals
  • Class
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders; Pain

Most Recent Events

  • 08 Mar 2004 Preclinical trials in CNS disorders in USA (unspecified route)
  • 08 Mar 2004 Preclinical trials in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top